S.Biomedics Co., Ltd. (KOSDAQ: 304360)
South Korea
· Delayed Price · Currency is KRW 18,860
-950 (-4.80%)
Nov 18, 2024, 1:21 PM KST
S.Biomedics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 11,901 | 13,108 | 12,113 | 8,868 | 5,319 | 5,014 | Upgrade
|
| Other Revenue | - | - | -0 | - | -0 | - | Upgrade
|
| Revenue | 11,901 | 13,108 | 12,113 | 8,868 | 5,319 | 5,014 | Upgrade
|
| Revenue Growth (YoY) | -13.70% | 8.22% | 36.58% | 66.72% | 6.09% | 58.65% | Upgrade
|
| Cost of Revenue | 5,986 | 6,555 | 6,002 | 4,549 | 4,022 | 4,053 | Upgrade
|
| Gross Profit | 5,915 | 6,554 | 6,111 | 4,319 | 1,298 | 961.24 | Upgrade
|
| Selling, General & Admin | 5,941 | 5,414 | 4,224 | 3,357 | 3,365 | 3,730 | Upgrade
|
| Research & Development | 5,895 | 6,508 | 5,489 | 5,525 | 5,559 | 5,927 | Upgrade
|
| Operating Expenses | 12,490 | 12,543 | 9,863 | 8,947 | 9,731 | 10,036 | Upgrade
|
| Operating Income | -6,576 | -5,989 | -3,752 | -4,628 | -8,433 | -9,075 | Upgrade
|
| Interest Expense | -883.54 | -883.54 | -727.42 | -674.93 | -514.96 | -365.96 | Upgrade
|
| Interest & Investment Income | 266.24 | 266.24 | 146.72 | 101.05 | 97.05 | 99.63 | Upgrade
|
| Currency Exchange Gain (Loss) | 39.53 | 39.53 | 17.21 | 91.56 | -16.89 | -6.34 | Upgrade
|
| Other Non Operating Income (Expenses) | -2,166 | 132.19 | -918.38 | -151.52 | 184.2 | 123.72 | Upgrade
|
| EBT Excluding Unusual Items | -9,319 | -6,435 | -5,234 | -5,262 | -8,684 | -9,223 | Upgrade
|
| Gain (Loss) on Sale of Investments | 92.61 | 92.61 | 23.87 | 0.24 | 89.31 | 208.6 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.49 | 5.49 | - | - | - | 0.07 | Upgrade
|
| Other Unusual Items | -0.48 | -0.48 | - | 12.82 | - | - | Upgrade
|
| Pretax Income | -9,222 | -6,337 | -5,210 | -5,249 | -8,594 | -9,015 | Upgrade
|
| Income Tax Expense | -116.74 | 123.24 | -455.23 | -6.59 | -4.55 | -2.15 | Upgrade
|
| Earnings From Continuing Operations | -9,105 | -6,460 | -4,755 | -5,242 | -8,590 | -9,013 | Upgrade
|
| Minority Interest in Earnings | -666.13 | -1,063 | -1,572 | -424.81 | 842.53 | 914.72 | Upgrade
|
| Net Income | -9,771 | -7,524 | -6,327 | -5,667 | -7,747 | -8,098 | Upgrade
|
| Net Income to Common | -9,771 | -7,524 | -6,327 | -5,667 | -7,747 | -8,098 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | 9.52% | 6.97% | 0.67% | 0.42% | 3.93% | 406.19% | Upgrade
|
| EPS (Basic) | -860.06 | -688.21 | -619.09 | -558.24 | -766.36 | -832.54 | Upgrade
|
| EPS (Diluted) | -860.06 | -688.21 | -619.09 | -558.24 | -766.36 | -832.54 | Upgrade
|
| Free Cash Flow | -7,303 | -7,996 | -12,501 | -3,762 | -5,620 | -7,468 | Upgrade
|
| Free Cash Flow Per Share | -642.81 | -731.44 | -1223.19 | -370.56 | -555.91 | -767.82 | Upgrade
|
| Gross Margin | 49.70% | 50.00% | 50.45% | 48.70% | 24.40% | 19.17% | Upgrade
|
| Operating Margin | -55.25% | -45.69% | -30.98% | -52.19% | -158.54% | -180.98% | Upgrade
|
| Profit Margin | -82.10% | -57.39% | -52.23% | -63.90% | -145.64% | -161.51% | Upgrade
|
| Free Cash Flow Margin | -61.36% | -61.00% | -103.20% | -42.42% | -105.65% | -148.95% | Upgrade
|
| EBITDA | -4,890 | -4,436 | -2,235 | -3,180 | -7,084 | -7,807 | Upgrade
|
| EBITDA Margin | -41.09% | -33.84% | -18.45% | -35.86% | -133.17% | -155.71% | Upgrade
|
| D&A For EBITDA | 1,685 | 1,553 | 1,517 | 1,448 | 1,349 | 1,267 | Upgrade
|
| EBIT | -6,576 | -5,989 | -3,752 | -4,628 | -8,433 | -9,075 | Upgrade
|
| EBIT Margin | -55.25% | -45.69% | -30.98% | -52.19% | -158.54% | -180.98% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.